Signature of the informed consent and consent to the use of personal data
Prostate Specific Antigen (PSA) \< 20 ng/mL
Unilateral organ-confined disease on MRI (performed according to ESUR recommendations and reported according to PiRads V.2) or PET-PSMA (performed according to the recommendations of the EANM and reported according to "EANM standardized reporting guidelines v1.0 for PSMA-PET")
Histological diagnosis of acinar-type prostate cancer unilateral on target biopsy and/or standard biopsy with ISUP \< 3 and ipsilateral on imaging investigations
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Life expectancy ≥ 5 years
Availability of the patient's pre-operative clinical data
Patients must be available to carry out the follow-up visits defined by the protocol
Absence of retroperitoneal, lymph nodal, bone or visceral metastatic lesions
Patients eligible for robot-assisted radical prostatectomy
You may not be if
Special histotypes of prostate cancer
Patients with PSA \> 20 ng/ml at diagnosis
Impossibility to perform MRI (with pacemakers, claustrophobia…) or PET-PSMA
Previous prostate surgery (TURP, adenomectomy)
Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies
Serious underlying disease or uncontrolled medical condition including active and uncontrolled infections
Patients with dementia or psychiatric illness that limit compliance with study requirements or that could prevent understanding and/or signing the informed consent.
